Stay updated with breaking news from 37555810. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Checchi Capital Advisers LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 11,171 shares of the biopharmaceutical company’s stock after selling 445 shares during the quarter. Checchi Capital Advisers […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price decreased by Barclays from $85.00 to $80.00 in a research note released on Monday morning, Benzinga reports. Barclays currently has an equal weight rating on the biopharmaceutical company’s stock. GILD has been the topic of a number of other research reports. UBS Group lowered their […]
Prudential PLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 219,527 shares of the biopharmaceutical company’s stock after purchasing an additional 14,657 shares during […]
Manchester Capital Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 21,657 shares of the biopharmaceutical company’s stock after purchasing an additional 468 shares during the period. Manchester Capital Management […]
Rhumbline Advisers grew its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.6% during the third quarter, Holdings Channel reports. The institutional investor owned 2,862,109 shares of the biopharmaceutical company’s stock after acquiring an additional 72,535 shares during the quarter. Rhumbline Advisers’ holdings in Gilead Sciences were worth $214,486,000 as of its most […]